Novo Nordisk ready to go toe to toe with Ascendis

Should Novo Nordisk end up in direct competition with Ascendis Pharma on the growth hormone market, the Danish pharmaceutical giant has an arsenal ready, including a network of doctors and payers, says CEO Lars Fruergaard Jørgensen.
Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Photo: Stine Bidstrup/ERH
Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Photo: Stine Bidstrup/ERH
by ANDREAS LØNSTRUP, translated by daniel pedersen

The stage is being set for a battle of the Danes, with pharmaceutical giant Novo Nordisk in one corner and biotech firm Ascendis Pharma, which is on the upswing, in the other.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading